Loading
Sentiment · FY2026 Q2
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $954M | +5.8% | $2.62 | +12.9% | 59.8% | 27.4% | 22.7% | $223M |
| FY2025 Q1 | $998M | +3.6% | $2.96 | +5.3% | 62.4% | 31.7% | 24.3% | $208M |
| FY2025 Q2 | $1.11B | +10.6% | $3.63 | +48.8% | 62.6% | 33.6% | 26.5% | $152M |
| FY2025 Q3 | $1.11B | +13.3% | $3.40 | +21.4% | 61.8% | 32.1% | 24.8% | $371M |
| FY2025 Q4 | $1.09B | +14.3% | $3.08 | +17.6% | 60.3% | 28.9% | 22.8% | $323M |
| FY2026 Q1 | $1.14B | +14.3% | $3.47 | +17.2% | 63.4% | 31.8% | 24.4% | $234M |
| FY2026 Q2 | $1.22B | +9.7% | $4.27 | +17.6% | 64.0% | 35.0% | 27.8% | $323M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
IDEXX delivered Q1 revenue up 14% as reported and 11% organically with comparable EPS growth of 15% as CAG Diagnostics recurring revenue grew over 11% organically on strong instrument placements and menu utilization gains. The FNA controlled launch progressed as planned, and international commercial expansion continued at a strong pace. Management raised full-year EPS guidance by $0.13 at midpoint to $14.45-$14.90 while noting the CEO transition with leadership continuity ensured.
Demand | Product Launch | Revenue Growth | Innovation & R&D | Macroeconomic | Competitive Dynamics | Geographic Expansion | Guidance Reliability | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 8 | 2 | 1 | 2 | 2 | 1 | 1 | |
| 2025Q1 | 7 | 4 | 2 | 1 | 3 | 1 | 1 | |
| 2025Q2 | 3 | 6 | 4 | 1 | 2 | 3 | 3 | |
| 2025Q3 | 4 | 6 | 3 | 3 | 1 | 3 | 2 | |
| 2025Q4 | 6 | 2 | 3 | 3 | 2 | 1 | 1 | 2 |
| 2026Q1 | 4 | 3 | 4 | 4 | 2 | 2 | 2 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 8 | 7 | 3 | 4 | 6 | 4 |
| Product Launch | 2 | 4 | 6 | 6 | 2 | 3 |
| Revenue Growth | 1 | 2 | 4 | 3 | 3 | 4 |
| Innovation & R&D | 2 | 1 | 1 | 3 | 3 | 4 |
| Macroeconomic | 2 | 3 | 1 | 2 | 2 | |
| Competitive Dynamics | 1 | 1 | 2 | 3 | 1 | 2 |
| Geographic Expansion | 1 | 3 | 2 | 1 | 2 | |
| Guidance Reliability | 1 | 3 | 2 | 1 |
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Erin Wright | Morgan Stanley | 14 (7%) |
| Mike Ryskin | Bank of America | 14 (7%) |
| Jon Block | Stifel | 14 (21%) |
| Dan Clark | Leerink Partners | 10 (0%) |
| Chris Schott | JPMorgan | 8 (0%) |
| Ryan Daniels | William Blair | 6 (0%) |
| Brandon Vazquez | William Blair | 4 (0%) |
| Navann Ty | BNP Paribas | 4 (25%) |
| David Westenberg | Piper Sandler | 3 (0%) |
| Daniel Grosslight | Citigroup | 3 (0%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Bank of America | 1 | 14 (7%) |
| Morgan Stanley | 1 | 14 (7%) |
| Stifel | 1 | 14 (21%) |
| William Blair | 2 |
| 10 (0%) |
| Leerink Partners | 1 | 10 (0%) |
| JPMorgan | 1 | 8 (0%) |
| BNP Paribas | 1 | 4 (25%) |
| Piper Sandler | 1 | 3 (0%) |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
IDXX Idexx Laboratories | 8 | +14.3% | |
| A Agilent Technologies | 6 | +7.0% | |
| CRL Charles River Laboratories | 4 | +1.2% | |
| DGX Quest Diagnostics | 9 | +9.2% | |
| DHR Danaher Corporation | 7 | +3.7% | |
| IQV IQVIA | 7 | +8.4% | |
| LH LabCorp | 8 | +5.8% | |
| MTD Mettler Toledo | 7 | +7.2% | |
| RVTY Revvity | 5 | +7.0% | |
| TMO Thermo Fisher Scientific | 7 | +6.2% | |
| WAT Waters Corporation | 9 | +91.5% |